Company
Delta-Fly Pharma, Inc.
Headquarters: Tokushima, Japan
Employees: 11
Market Cap
¥4.38 Billion
JPY as of Jan. 1, 2025
US$27.9 Million
Delta-Fly Pharma, Inc. Categories
Japan Healthcare BiotechnologyJapan Healthcare Japan Biotechnology
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $622.07 B |
| Vertex Pharmaceuticals Incorporated | $113.24 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $76.33 B |
| Marinomed Biotech AG | $56.13 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Detailed Description
Delta-Fly Pharma, Inc. develops anticancer drugs. It develops DFP-10917 for the treatment of relapsed/refractory acute myeloid leukemia; DFP-14323 to treat lung cancer; DFP-17729, DFP-11207, and DFP-14927 for the treatment of solid tumors; and DFP-10825 for peritoneal metastasis. The company was founded in 2010 and is headquartered in Tokushima, Japan.
Top 1-year algo backtest: +327.04%
$10,000 in March 2024 would now be $42,704 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Stocks & Indices
Delta-Fly Pharma, Inc. has the following listings and related stock indices.
Stock: JPX: 4598 wb_incandescent